Skip to Content
  • Mongersen Fails

    Readers may recall a post here last year about an odd trial of an antisense drug for Crohn’s disease. Celgene had acquired the drug (mongersen, GED-301)… Read More
  • A Bit About Biopharma Investing

    Well, as predicted here (and many other places), Merck announced yesterday that they are indeed not going to try to seek approval for their CETP inhibitor, anac… Read More
  • It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a respons… Read More
  • Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage need… Read More
  • Lilly Cuts Back, Again

    The Big Pharma story at the moment, sad to say, is that Eli Lilly is shedding a lot of employees: 3,500 or so (2000 of them in the US), about 8.5% of their glob… Read More
  • Good Craziness and Bad Craziness

    It’s fair to say that there’s a high level of excitement these days in biopharma (and the associated academic disciplines) due to the tools we have… Read More
  • GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days… Read More
Page 1 of 10212345...102030...Last »